Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17329132 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAATSHREPHX1MEN1 | |
| SCHEMBL31402060 | 0.82 | ALDH1A1 (0.41) | ALDH1A1GAATSHREPHX1MEN1 | |
| SCHEMBL15204759 | 0.81 | ALDH1A1 (0.49) | ALDH1A1GAATSHREPHX1MEN1 | |
| SCHEMBL15204757 | 0.81 | ALDH1A1 (0.49) | ALDH1A1GAATSHREPHX1MEN1 | |
| SCHEMBL8069476 | 0.81 | HPGD (0.47) | ALDH1A1GAATSHRMEN1KMT2A | |
| SCHEMBL140115 | 0.80 | ALDH1A1 (0.43) | ALDH1A1GAATSHRMEN1KMT2A | |
| SCHEMBL3401836 | 0.80 | CTSL (0.45) | ALDH1A1GAATSHRMEN1KMT2A | |
| SCHEMBL9885083 | 0.80 | DRD2 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL942085 | 0.80 | DRD2 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL942084 | 0.80 | DRD2 (0.46) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014123167-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | 日産化学工業株式会社 (JP) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | JAK1, JAK2, JAK3 | ALDH1A1 3494/4885GAA 4353/4885TSHR 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.